Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting
Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data presentations at its product theaters, advisory boards, and booth activities onsite as AAD returns in-person once more.
“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovation and data across our complete dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Our presence underscores our commitment to developing and bringing to market dermatological solutions to address every skin need.”
A considerable amount of new data will be presented during the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, under clinical development for the treatment of atopic dermatitis and prurigo nodularis.
The data for prurigo nodularis include efficacy data of nemolizumab and its impact on itch and sleep disturbance. An additional seven abstracts look at a variety of aspects of the disease including its prevalence, current treatment practices and the effect of the disease on sleep, mental health disorders and gastrointestinal and hepatobiliary diseases. Three abstracts in atopic dermatitis look at the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to EASI and Scorad components.
Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. Data comes from Phase 2 studies and real-world evidence. More details on Galderma’s activities can be found below.
Abstract # and Title | First Author | Presentation Date/Time (ET) |
Abstract #35226: Characterization of Pain in Prurigo Nodularis: An Online Survey-Based Study | Prachi Aggarwal, BA | Friday, March 25, 8:35 – 8:40 AM |
Abstract #35303: Treatment Practices and the Use of Web-based Resources in Prurigo Nodularis | Prachi Aggarwal, BA | Friday, March 25, 8:40 – 8:45 AM |
Abstract #35351: Association between prurigo nodularis and gastrointestinal and hepatobiliary diseases in adults: A national cross-sectional study. | Adawi Waleed | Friday, March 25, 8:55 – 9:00 AM |
Abstract #35165: Efficacy, Tolerability, and Cosmetic Acceptability of an Acne Regimen Specifically Designed for Sensitive Skin | James Q. Del Rosso, DO | Friday, March 25 8:55 – 9:00 AM |
Abstract #32846: DUAL Study: Trifarotene Plus Doxycycline Has Proven Efficacy and Safety in Severe Acne Vulgaris | James Q. Del Rosso, DO | Friday, March 25 9:00 – 9:05 AM |
Abstract #33284: Efficacy of nemolizumab in atopic dermatitis: Rapid impact on EASI and SCORAD components | Jean-David Bouaziz, MD, PhD | Friday, March 25 11:15 – 11:20 AM |
Abstract #33317: Study of nemolizumab pharmacokinetics, safety, and efficacy in adolescents with atopic dermatitis | Robert Sidbury, MD, MPH | Friday, March 25 11:20 – 11:25 AM |
Abstract #34945: An In-vitro Evaluation of a Niacinamide-Panthenol-Glycerin Complex on Skin Barrier Function, Hydration, and Neuro-Inflammation | Dillon Nussbaum, BSc | Friday, March 25 11:55 – 12:00 PM |
Abstract #34679: Association of adult atopic dermatitis severity with decreased physical activity: A cross-sectional study | Gabrielle Schwartzman | Friday, March 25 2:20 – 2:25 PM |
Abstract #35218: Sleep disturbance in adults with prurigo nodularis is associated with increased circulating C-reactive protein levels and adverse cardiovascular outcomes | Varsha Parthasarathy | Friday, March 25, 2:25 – 2:30 PM |
Abstract #33202: Prurigo nodularis and mental health disorders among hospitalized patients in the United States | Thomas K Le | Saturday, March 26, 1:25 – 1:30 PM |
Abstract #34095: Observed and Projected Prevalence of Prurigo Nodularis in a Commercially and Medicare-insured U.S. Population | Shawn G. Kwatra | Saturday, March 26, 2:40 – 2:45 PM |
Abstract #33307: Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis | Sonja Ständer, MD | E-Poster |
Additionally, Galderma will be hosting four product theaters to discuss new research findings across our portfolio:
Product | Topic | Date/Time (ET) | Location |
Acne: TWYNEO Cream & AKLIEF Cream | Groundbreaking Acne Treatment: TWYNEO Cream: Dermatology’s Only Combination .1% Tretinoin and 3% BPO for Moderate to Severe Acne Vulgaris | Friday, March 25 10:30 – 11:15 AM | Theater 2 |
CETAPHIL Sensitive Skin | Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology | Friday, March 25 12:00 – 12:45 PM | Theater 1 |
CETAPHIL Pediatric | Paediatric Atopic Dermatitis: Current Developments | Saturday, March 26 12:00 – 12:45 PM | Theater 2 |
IL-31 | A Neuroimmune Perspective on Itch and Skin Inflammation in Atopic Dermatitis and Prurigo Nodularis – Introducing IL-31 | Sunday, March 27 10:30 – 11:15 AM | Theater 2 |
A series of Speakers Forum talks will be held on the Galderma booth #1117.
Topic | Speaker | Date/Time (ET) | Location |
IL-31: A Neuroimmune Perspective of Atopic Dermatitis | Jonathan Silverberg, MD, PhD, MPH | Friday, March 25 12:10 – 12:25 PM | Galderma booth #1117 |
Activate Skin Power with PLLA | Susan H. Weinkle, MD | Friday, March 25 12:30 – 12:55 PM | Galderma booth #1117 |
Galderma Innovation | JP York, PhD, Galderma Medical Affairs | Saturday, March 26 12:10 – 12:25 PM | Galderma booth #1117 |
Groundbreaking Acne Treatment: TWYNEO Cream: Dermatology’s Only Combination .1% Tretinoin and 3% BPO for Moderate to Severe Acne Vulgaris | Omar Noor, MD, FAAD | Saturday, March 26 12:30 – 12:55 PM | Galderma booth #1117 |
The Rheology of Restylane Collection of Hyaluronic Acid Fillers | Deirdre Hooper, MD | Sunday, March 27 12:10 – 12:55 PM | Galderma booth #1117 |
For more information on IL-31 and its role in the pathophysiology of atopic dermatitis and prurigo nodularis, visit www.IL31role.com.
About atopic dermatitis
Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.[1],[2] Reported prevalence of AD varies greatly, ranging from 1% to 25% of the population depending on the geography and age range.[3] AD can have a profound impact on patients’ quality of life, leading to sleep difficulties, psychological complications and causing secondary skin infections (bacterial and viral).[4]
About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.[5] While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.[6]
The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000.[4] In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.[6]
About nemolizumab
Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com/us.
References
- Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
- Weidinger S. et al. Atopic dermatis. Nature Reviews. 2018. DOI: 10.1038/s41572-018-0001-z
- Silverberg, J, I. Public Health Burden and Epidemiology of Atopic Dermatitis.283-289. 2017.
- Galderma. Data on File. To be presented at AAD 2022.
- Galderma. Data on File. Press Release. Galderma presents new nemolizumab data at EADV. 2021.
- Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. Accepted for publication in British Journal of Dermatology
- Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005215/en/
Contact information
Media Relations
Shannon Iwaniuk
Director, U.S. Communications
shannon.iwaniuk@galderma.com
+1 720 308 1336
Rachel Mooney
Director, Global Franchise Communications
rachel.mooney@galderma.com
+41 58 455 85 41 /+41 76 261 64 41
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo